MariMed Inc. (MRMD) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago.
MariMed Inc. (MRMD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
MariMed Inc. (OTCQX:MRMD) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Jake Dean - Director of Research and Development Jon R. Levine - Co-Founder, CEO, President, Secretary, Treasurer & Director Mario Pinho - Chief Financial Officer Ryan Crandall - Chief Commercial Officer Conference Call Participants Andrew Semple - Ventum Financial Corp., Research Division Joseph Anthony Gomes - NOBLE Capital Markets, Inc., Research Division Pablo Ernesto Zuanic - Zuanic & Associates Operator Good morning.
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Jon R. Levine CEO | OTCQX Exchange | US56782V1070 ISIN |
| US Country | 643 Employees | - Last Dividend | - Last Split | - IPO Date |
MariMed Inc. is a distinguished entity in the cannabis industry, focusing on the cultivation, production, and dispensing of both medicinal and recreational cannabis across the United States and internationally. With its incorporation in 2011 and headquarters in Norwood, Massachusetts, MariMed has carved a niche for itself by offering a wide range of high-quality cannabis products under several well-recognized brands. The company operates with a commitment to excellence and innovation in the cannabis space, ensuring that it meets the diverse needs of its customers through exceptional product offerings and services.